ES2517040B2 - Nanoparticles for the controlled release of active ingredients - Google Patents
Nanoparticles for the controlled release of active ingredients Download PDFInfo
- Publication number
- ES2517040B2 ES2517040B2 ES201330625A ES201330625A ES2517040B2 ES 2517040 B2 ES2517040 B2 ES 2517040B2 ES 201330625 A ES201330625 A ES 201330625A ES 201330625 A ES201330625 A ES 201330625A ES 2517040 B2 ES2517040 B2 ES 2517040B2
- Authority
- ES
- Spain
- Prior art keywords
- nanoparticles
- active ingredient
- active ingredients
- controlled release
- hyaluronic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Medical Informatics (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cosmetics (AREA)
Abstract
Nanopartículas para la liberación controlada de ingredientes activos, las cuales comprenden quitosano, ácido hialurónico y colágeno y además incorporan un ingrediente activo; un procedimiento para la obtención de dichas nanopartículas, el cual implica la transformación de una fase líquida, que contiene los polímeros en una fase sólida, que a su vez contiene el ingrediente activo que cumple con la forma requerida para ser administrada con un perfil de liberación controlada y que, además, permite la incorporación directa del ingrediente activo preservando su integridad o acción terapéutica, y uso de las nanopartículas para la fabricación de composiciones farmacéuticas o cosméticas.Nanoparticles for the controlled release of active ingredients, which comprise chitosan, hyaluronic acid and collagen and also incorporate an active ingredient; a process for obtaining said nanoparticles, which involves the transformation of a liquid phase, which contains the polymers in a solid phase, which in turn contains the active ingredient that complies with the form required to be administered with a release profile controlled and that, in addition, allows the direct incorporation of the active ingredient preserving its integrity or therapeutic action, and use of nanoparticles for the manufacture of pharmaceutical or cosmetic compositions.
Description
P201330625 P201330625
30-04-2013 04-30-2013
Figura 5: Gráfico de % de liberación de antioxidantes vs. tiempo (horas), a partir de nanopartículas que comprenden quitosano, ácido hialurónico y colágeno con un 20% de extracto de hojas de olivo encapsulado, según unas formulaciones a), b), c) y d), que corresponden respectivamente a relaciones en masa de 9:1:2, 2:1:9, 1:1:2 y 2:3:6. Figure 5: Chart of% antioxidant release vs. time (hours), from nanoparticles comprising chitosan, hyaluronic acid and collagen with 20% encapsulated olive leaf extract, according to formulations a), b), c) and d), which correspond respectively to mass ratios of 9: 1: 2, 2: 1: 9, 1: 1: 2 and 2: 3: 6.
EJEMPLOS En los ejemplos de la presente invención se emplean las siguientes abreviaturas: HCS: Hidrocloruro de quitosano HA: Ácido hialurónico Col: Colágeno TPP: Tripolifosfato sódico BSA: Albúmina de suero bovino OLE: Extracto de hojas de olivo NPs: Nanopartículas EXAMPLES In the examples of the present invention the following abbreviations are used: HCS: Chitosan hydrochloride HA: Hyaluronic acid Col: Collagen TPP: Sodium tripolyphosphate BSA: Bovine serum albumin OLE: Olive leaf extract NPs: Nanoparticles
Ejemplo 1 Se prepararon nanopartículas de hidrocloruro de quitosano, ácido hialurónico y colágeno, utilizando tripolifosfato sódico como agente entrecruzante. Se adicionó la disolución de ácido hialurónico (3 mg/ml) y tripolifosfato sódico (0,1%) sobre la disolución que contiene hidrocloruro de quitosano (0,15%), bajo agitación constante y durante 10 minutos, permitiendo la estabilización de las nanopartículas generadas. Se procedió a la centrifugación de éstas con objeto de eliminar los posibles residuos de quitosano y ácido hialurónico sin reaccionar y el pellet resultante se vuelve a suspender en una disolución de colágeno (5 mg/ml) durante 2 horas, en agitación constante. Posteriormente, se añadió una cantidad adecuada de tripolifosfato sódico y se deja reaccionar 30 minutos, permitiendo la completa evolución del sistema hasta la obtención de nanopartículas estables. Una vez preparadas, se midió su diámetro medio (nm), así como su carga eléctrica superficial y se estudió su morfología mediante microscopía electrónica de transmisión. En la tabla 1, para todo el rango de concentraciones y en las figuras 1 y 4, para unas concentraciones deterrminadas, se muestran algunos de los valores que toman los parámetros citados en función de la proporción de HCS, HA, Col y TPP utilizados. Example 1 Chitosan hydrochloride, hyaluronic acid and collagen nanoparticles were prepared, using sodium tripolyphosphate as the crosslinking agent. The solution of hyaluronic acid (3 mg / ml) and sodium tripolyphosphate (0.1%) was added to the solution containing chitosan hydrochloride (0.15%), under constant stirring and for 10 minutes, allowing the stabilization of the generated nanoparticles. The centrifugation of these was carried out in order to eliminate the possible unreacted chitosan and hyaluronic acid residues and the resulting pellet is resuspended in a collagen solution (5 mg / ml) for 2 hours, under constant stirring. Subsequently, an adequate amount of sodium tripolyphosphate was added and allowed to react for 30 minutes, allowing the complete evolution of the system until obtaining stable nanoparticles. Once prepared, its average diameter (nm) was measured, as well as its surface electric charge and its morphology was studied by transmission electron microscopy. Table 1, for the entire range of concentrations and in Figures 1 and 4, for certain concentrations determined, some of the values that take the parameters mentioned according to the proportion of HCS, HA, Col and TPP used are shown.
Tabla 1 Table 1
9 9
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES201330625A ES2517040B2 (en) | 2013-04-30 | 2013-04-30 | Nanoparticles for the controlled release of active ingredients |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES201330625A ES2517040B2 (en) | 2013-04-30 | 2013-04-30 | Nanoparticles for the controlled release of active ingredients |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ES2517040A1 ES2517040A1 (en) | 2014-10-31 |
| ES2517040B2 true ES2517040B2 (en) | 2015-04-29 |
Family
ID=51795080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES201330625A Expired - Fee Related ES2517040B2 (en) | 2013-04-30 | 2013-04-30 | Nanoparticles for the controlled release of active ingredients |
Country Status (1)
| Country | Link |
|---|---|
| ES (1) | ES2517040B2 (en) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4476600A (en) * | 1999-04-22 | 2000-11-10 | Vanderbilt University | Polymeric encapsulation system promoting angiogenesis |
-
2013
- 2013-04-30 ES ES201330625A patent/ES2517040B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ES2517040A1 (en) | 2014-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2019036008A8 (en) | Lipids for use in lipid nanoparticle formulations | |
| Fathalla et al. | In-vitro and in-vivo evaluation of niosomal gel containing aceclofenac for sustained drug delivery | |
| EA201591003A1 (en) | DERIVATIVES OF BORONIC ACID AND THEIR THERAPEUTIC APPLICATION | |
| MX2013013401A (en) | Controlled release peptide formulations. | |
| CO6612270A2 (en) | Method for preparing an enteric hard capsule and enteric hard capsule prepared by it | |
| AR105203A1 (en) | SOLID ORAL FORMULATION CONTAINING IRINOTECAN AND METHOD OF PREPARATION OF THE SAME | |
| PH12016501519A1 (en) | Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions | |
| MX346661B (en) | Stabilized eperisone medical composition, and sustained-release preparation containing same. | |
| PE20171246A1 (en) | PHARMACEUTICAL FORMULATIONS THAT INCLUDE HIGH PURITY CANGRELOR AND METHODS FOR THE PREPARATION AND USE OF SAME | |
| EA202092926A2 (en) | LYOPHILIZED COMPOSITIONS CONTAINING FACTOR IX | |
| EA201991023A1 (en) | PHARMACEUTICAL COMPOSITION FOR Parenteral Administration Containing Karglum Acid | |
| WO2016040814A3 (en) | Disulfide polymers and methods of use | |
| ES2517040B2 (en) | Nanoparticles for the controlled release of active ingredients | |
| JP2015511618A5 (en) | ||
| PH12015502717A1 (en) | Anti-fibrogenic compounds, methods and uses thereof | |
| MX2020005921A (en) | Formulations and methods for vaginal delivery of antiprogestins. | |
| RU2017141462A (en) | COMPOSITION CONTAINING NORBIXIN FOR PROTECTION OF CELL PIGMENT EPITHELIUM CELLS | |
| JP2016507535A5 (en) | ||
| RU2015145451A (en) | PRODUCTS FOR LOCAL USE CONTAINING HYALURONIC ACID, VERBASCOZIDE AND GLYCEROPHOSPHOINOSITOL | |
| MX2020002347A (en) | Use of physiological cooling active ingredients, and compositions comprising such active ingredients. | |
| CN103751214A (en) | Alligator oil nano-liposome and preparation method thereof | |
| ZA201905738B (en) | Conjugate of salicylic acid and peptide | |
| MX370974B (en) | Preparation of zinc citrate and of zinc citrate-containing oral care compositions. | |
| CA2903759C (en) | Concentrated aqueous azalide formulations | |
| TAN | Preparation, characteristic and in vivo study of H102 loaded PEG-PLGA nanoparticles |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 2517040 Country of ref document: ES Kind code of ref document: B2 Effective date: 20150429 |
|
| FD2A | Announcement of lapse in spain |
Effective date: 20220701 |